Advance Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.21M Buy
2,678
+2,199
+459% +$2.25M 0.1% 38
2026
Q1
$441K Buy
479
+22
+5% +$22.3K 0.02% 114
2025
Q4
$491K Buy
457
+19
+4% +$18.2K 0.02% 106
2025
Q3
$334K Buy
438
+136
+45% +$101K 0.01% 130
2025
Q2
$236K Sell
302
-27
-8% -$21K 0.01% 150
2025
Q1
$272K Buy
329
+16
+5% +$13.3K 0.01% 127
2024
Q4
$242K Buy
313
+7
+2% +$5.8K 0.01% 134
2024
Q3
$271K Hold
306
0.01% 125
2024
Q2
$277K Buy
306
+19
+7% +$15.2K 0.01% 124
2024
Q1
$223K Buy
+287
New +$204K 0.02% 138
2023
Q4
Sell
-729
Closed -$392K 134
2023
Q3
$392K Buy
729
+39
+6% +$20.1K 0.04% 78
2023
Q2
$324K Buy
690
+37
+6% +$15.5K 0.04% 86
2023
Q1
$224K Hold
653
0.04% 92
2022
Q4
$239K Sell
653
-17
-3% -$6.03K 0.03% 95
2022
Q3
$217K Hold
670
0.03% 82
2022
Q2
$217K Buy
+670
New +$201K 0.03% 77

Other funds holding LLY

Advance Capital Management's LLY Position: Q2 2026 in Review

Advance Capital Management increased its Eli Lilly (LLY) stake by 459% in Q2 2026, buying an estimated $2.25M and bringing the position to 2,678 shares worth $3.21M. The position accounts for 0.1% of the portfolio, ranked #38.

Advance Capital Management first reported a position in LLY in Q2 2022 and has held it in 16 quarters since. 4,635 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Advance Capital Management held 2,678 shares of Eli Lilly worth $3.21M as of Q2 2026.
  • Advance Capital Management bought 2,199 Eli Lilly shares in Q2 2026, an estimated $2.25M.
  • Eli Lilly made up 0.1% of Advance Capital Management's portfolio in Q2 2026, its #38 holding.
  • Advance Capital Management first reported a position in Eli Lilly in Q2 2022 and has held it in 16 quarters since.
  • 4,635 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Advance Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.